Qian JL, Wang J, Shen ZY, Xu BQ, Shen DP, Yang C. Effect of nalbuphine on analgesia and pain factors after gastric cancer resection. World J Gastrointest Surg 2025; 17(1): 99327 [DOI: 10.4240/wjgs.v17.i1.99327]
Corresponding Author of This Article
Cheng Yang, Department of Anesthesiology, Suzhou Ninth People’s Hospital, No. 2666 Ludang Road, Taihu Lake New Town, Wujiang District, Suzhou 215299, Jiangsu Province, China. 17798652510@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Randomized Controlled Trial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Jan 27, 2025; 17(1): 99327 Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.99327
Effect of nalbuphine on analgesia and pain factors after gastric cancer resection
Jia-Li Qian, Jie Wang, Zi-Yi Shen, Bao-Qin Xu, Dan-Ping Shen, Cheng Yang
Jia-Li Qian, Jie Wang, Zi-Yi Shen, Bao-Qin Xu, Dan-Ping Shen, Cheng Yang, Department of Anesthesiology, Suzhou Ninth People’s Hospital, Suzhou 215299, Jiangsu Province, China
Author contributions: Qian JL designed the research study; Qian JL, Wang J, Shen ZY, Xu BQ, Shen DP, and Yang C performed the research, and contributed to the new reagents and analytical tools; Qian JL and Yang C analyzed the data and wrote the manuscript; and all authors have read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Suzhou Ninth People’s Hospital, No. KYLW2024-050-01.
Clinical trial registration statement: The study was registered at the Clinical Trial Center (www.researchregistry.com) with registration number: Researchregistry10725.
Informed consent statement: All study participants and their legal guardians provided written informed consent before enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cheng Yang, Department of Anesthesiology, Suzhou Ninth People’s Hospital, No. 2666 Ludang Road, Taihu Lake New Town, Wujiang District, Suzhou 215299, Jiangsu Province, China. 17798652510@163.com
Received: September 6, 2024 Revised: September 25, 2024 Accepted: November 8, 2024 Published online: January 27, 2025 Processing time: 112 Days and 5.6 Hours
Abstract
BACKGROUND
Gastric cancer (GC) is a prevalent tumor in the digestive system, with around one million new cases reported annually, ranking it as the third most common malignancy. Reducing pain is a key research focus. This study evaluates the effect of nalbuphine on the analgesic effect and the expression of pain factors in patients after radical resection.
AIM
To provide a reference for postoperative analgesia methods.
METHODS
One hundred eight patients with GC, admitted between January 2022 and June 2024, underwent radical gastrectomy. They received a controlled analgesia pump and a transverse abdominis muscle plane block, divided into two groups of 54 patients in each group. The control group received sufentanil, while the observation group received nalbuphine as an analgesic. Postoperative analgesic effects, pain factor expression, and adverse effects were compared.
RESULTS
The resting pain and activity pain scores in the observation group at 6, 12, 24 and 48 hours were significantly lower than those in the control group. Additionally, the number of presses and consumption of the observation group at 48 hours were lower than those of the control group; and the response rate of the observation group was higher than that of the control group (P < 0.05). The prostaglandin E2, substance P, and serotonin levels 24 hours after the observation group were lower than those in the control group, and the incidence of adverse reactions was 5.56% lower than 22.22% in the control group (P < 0.05).
CONCLUSION
The findings suggest that nalbuphine enhances postoperative multimodal analgesia in patients with radical GC, effectively improving postoperative analgesic effect, relieving postoperative resting and active pain, and reducing postoperative pain factor expression, demonstrating its potential for clinical application.
Core Tip: Nalbuphine, recognized for its potent analgesic properties, plays a crucial role in significantly enhancing postoperative pain management for patients who have undergone radical gastrectomy. Nalbuphine stands out due to its lower frequency of adverse reactions compared to other analgesics, which is a significant advantage in clinical settings. This lower incidence of side effects, coupled with its efficacy, positions nalbuphine as a promising candidate for improving patient recovery and overall comfort in the postoperative period, potentially leading to better patient outcomes and satisfaction.
